The Grizzly, April 29, 2004

As the School Years Ends, The Search for Jobs Begins • Life-Changing Volunteer Work Found At the Clinic • Fad Diets: Do They Work? • Opinions: Chronic Back Pain: Ouch!; Lacking Luster (Again) at La Fontana; Is Donald Trump the Ideal Boss?; Eating Your Veggies Now More Appetizing than Mom Tried to Make it • Staff Spotlight: Jamal Elliot • Ursinus Students Put Learning Into Practice at Model U.N. • Goldwater Scholar Kari Baker • Softball Team Rolls Past Muhlenberg • Leadership: A Key Ingredient in the Success of the Men\u27s Baseball Team • Final Exam Schedulehttps://digitalcommons.ursinus.edu/grizzlynews/1561/thumbnail.jp

The Grizzly, April 22, 2004

A Booming Economy Gives Way to a Promising Job Outlook • Spotlights on 2004 Salutatorians: Jacqueline Carrick and Quinn Dinsmore • Politics in Action: Photo Essay • Opinions: Business Degree = Job?; Cool Defined; Condoleeza Rice: Truth or Cover-up? • Student Spotlight: Nicole Borocci Making Headlines • New Play to Open this Week • Spring Fling 2004 • Skinner Dominating Centennial Conference • Herrmann, Bown Rack up CC Baseball Honorshttps://digitalcommons.ursinus.edu/grizzlynews/1560/thumbnail.jp

The Lantern Vol. 72, No. 2, Spring 2005

• Transmigration • Faces of the Moon • Euphony of the Euphonium • He Met Me in the Arcs & Ebbs of Frailty • An Adoration of Ordination • Ebony: The Essence Thereof • Curbside Statue Has No Legs Left • Triggerfinger Romance • Lost • Running Through Connecticut • Eve • The Day Lates and the Dollar Shorts • Somnambulist • That\u27s That • The Glenn Machine • Evenfall in Bad Homburg • Absence of Field • Dating Myself • Traveling Without a Map • The Non-Euclidean Way to Get Some Bagels • La Belle Epoque • Satin Boxeshttps://digitalcommons.ursinus.edu/lantern/1166/thumbnail.jp

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance

In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3B expression in EGFR mutant (EGFRmut) non-small-cell lung cancer (NSCLC) mouse models constrained tumorigenesis, while A3B expression in tumors treated with EGFR-targeted cancer therapy was associated with treatment resistance. Analyses of human NSCLC models treated with EGFR-targeted therapy showed upregulation of A3B and revealed therapy-induced activation of nuclear factor kappa B (NF-κB) as an inducer of A3B expression. Significantly reduced viability was observed with A3B deficiency, and A3B was required for the enrichment of APOBEC mutation signatures, in targeted therapy-treated human NSCLC preclinical models. Upregulation of A3B was confirmed in patients with NSCLC treated with EGFR-targeted therapy. This study uncovers the multifaceted roles of A3B in NSCLC and identifies A3B as a potential target for more durable responses to targeted cancer therapy.</p